© 2021 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
The FDA's Jan. 31 approval of Amevive (alefacept) for chronic plaque psoriasis represents the first step down an exciting new road, said Alan Menter, M.D, medical director of the Psoriasis Research Center at Baylor University Medical Center.